84 related articles for article (PubMed ID: 26752621)
1. Metabotropic glutamate2/3 receptor agonism facilitates autonomic recovery after pharmacological panic challenge in healthy humans.
Agorastos A; Demiralay C; Stiedl O; Muhtz C; Wiedemann K; Kellner M
Int Clin Psychopharmacol; 2016 May; 31(3):176-8. PubMed ID: 26752621
[TBL] [Abstract][Full Text] [Related]
2. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
Kellner M; Muhtz C; Stark K; Yassouridis A; Arlt J; Wiedemann K
Psychopharmacology (Berl); 2005 Apr; 179(1):310-5. PubMed ID: 15821951
[TBL] [Abstract][Full Text] [Related]
3. Blunted autonomic reactivity to pharmacological panic challenge under long-term escitalopram treatment in healthy men.
Agorastos A; Kellner M; Stiedl O; Muhtz C; Wiedemann K; Demiralay C
Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25522396
[TBL] [Abstract][Full Text] [Related]
4. The 5-HTTLPR genotype modulates heart rate variability and its adjustment by pharmacological panic challenge in healthy men.
Agorastos A; Kellner M; Stiedl O; Muhtz C; Becktepe JS; Wiedemann K; Demiralay C
J Psychiatr Res; 2014 Mar; 50():51-8. PubMed ID: 24342768
[TBL] [Abstract][Full Text] [Related]
5. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
[TBL] [Abstract][Full Text] [Related]
6. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats.
Shekhar A; Keim SR
Neuropharmacology; 2000 Apr; 39(7):1139-46. PubMed ID: 10760357
[TBL] [Abstract][Full Text] [Related]
7. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
Bradwejn J; Koszycki D; Paradis M; Reece P; Hinton J; Sedman A
Biol Psychiatry; 1995 Dec; 38(11):742-6. PubMed ID: 8580227
[TBL] [Abstract][Full Text] [Related]
8. The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers.
Katzman MA; Duffin J; Shlik J; Bradwejn J
Neuropsychopharmacology; 2002 Jun; 26(6):824-31. PubMed ID: 12007753
[TBL] [Abstract][Full Text] [Related]
9. Effects of low-dose cholecystokinin on respiratory function in healthy volunteers.
Schruers K; Caycedo N; Overbeek T; Büchold H; Bourin M; Griez E
Eur Neuropsychopharmacol; 2000 Sep; 10(5):419-21. PubMed ID: 10974616
[TBL] [Abstract][Full Text] [Related]
10. Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344).
Varma MV; Eriksson AH; Sawada G; Pak YA; Perkins EJ; Zimmerman CL
Drug Metab Dispos; 2009 Jan; 37(1):211-20. PubMed ID: 18838508
[TBL] [Abstract][Full Text] [Related]
11. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
Schunck T; Mathis A; Erb G; Namer IJ; Hode Y; Demazières A; Luthringer R
J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136
[TBL] [Abstract][Full Text] [Related]
12. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers.
Shlik J; Vasar V; Aluoja A; Kingisepp PH; Jagomägi K; Vasar E; Rägo L; Bradwejn J
Biol Psychiatry; 1997 Aug; 42(3):206-12. PubMed ID: 9232213
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Dunayevich E; Erickson J; Levine L; Landbloom R; Schoepp DD; Tollefson GD
Neuropsychopharmacology; 2008 Jun; 33(7):1603-10. PubMed ID: 17712352
[TBL] [Abstract][Full Text] [Related]
14. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
Zwanzger P; Eser D; Aicher S; Schüle C; Baghai TC; Padberg F; Ella R; Möller HJ; Rupprecht R
Neuropsychopharmacology; 2003 May; 28(5):979-84. PubMed ID: 12700707
[TBL] [Abstract][Full Text] [Related]
15. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers.
Koszycki D; Zacharko RM; Le Melledo JM; Young SN; Bradwejn J
Biol Psychiatry; 1996 Oct; 40(7):648-55. PubMed ID: 8886299
[TBL] [Abstract][Full Text] [Related]
16. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
McCann UD; Slate SO; Geraci M; Uhde TW
Anxiety; 1994-1995; 1(6):258-67. PubMed ID: 9160584
[TBL] [Abstract][Full Text] [Related]
17. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740.
Bergink V; Westenberg HG
Int Clin Psychopharmacol; 2005 Nov; 20(6):291-3. PubMed ID: 16192835
[TBL] [Abstract][Full Text] [Related]
18. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
Bradwejn J; Koszycki D; Shriqui C
Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
[TBL] [Abstract][Full Text] [Related]
19. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
Tõru I; Maron E; Raag M; Vasar V; Nutt DJ; Shlik J
Eur Neuropsychopharmacol; 2013 Jul; 23(7):645-52. PubMed ID: 22939006
[TBL] [Abstract][Full Text] [Related]
20. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
